Journal
MOLECULAR PHARMACEUTICS
Volume 15, Issue 2, Pages 527-535Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00893
Keywords
folic acid-Poloxamer 407 conjugate; folic acid-Poloxamer 407 nanoparticles; nanoparticle disruption; specific drug release; cancer therapy
Funding
- Portuguese Foundation for Science and Technology (FCT) [UID/BIO/04469/2013, SFRH/BPD/85790/2012]
- COMPETE [POCI-01-0145-FEDER-006684]
- BioTec-Norte operation - European Regional Development Fund under the scope of Norte-Programa Operational Regional do Norte [NORTE-01-0145-FEDER-000004]
- European Union [NMP-06-2015-683356 FOLSMART]
Ask authors/readers for more resources
Novel nanoparticles based on Poloxamer 407 and vegetable oil were produced by high pressure homogenization. Functionalization of those nanoparticles was made by incorporation of folic acid (FA)-Poloxamer 407 conjugate. These nanoparticles showed suitable characteristics for intravenous therapeutic applications similarly to PEGylated albumin-based nanoparticles, previously described by our research group. Here, we found that the absence of albumin at the interface of Poloxamer 407-based nanoparticles improves the overall process of in vitro cellular uptake and nanoparticle disruption inside cancer cells (folate receptor, FR, positive cells). The results presented here suggest that interfacial composition of those nanoparticles is of paramount importance for drug trafficking inside cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available